Showing 351-360 of 3932 results for "".
Which Probiotic for Which Disease? Part 1
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-1/23550/Enhanced interest in probiotics means clinicians need to pick the best strain for common dermatologic conditions."Ask Me Anything" Mentorship Session With Dr. Tina Bhutani
https://practicaldermatology.com/programs/practical-dermatology/ask-me-anything-mentorship-session-with-dr-tina-bhutani/39251/Tina Bhutani, MD, MAS, FAAD, describes her career journey and answers various questions from YoungMD Connect members. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank our silver platform sponsor, Incyte, and bronze sponsor, AlmiralPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 1
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-1/32757/In the first installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, provide an overview of generalized pustular psoriasis, including the unique challenges it poses, triggers associated with it, and the importance ofPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 5
https://practicaldermatology.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-5/32903/Host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, discuss getting clinicians out of the mindset of using traditional IL-17 and IL-23 blockers for generalized pustular psoriasis, understanding that it is a chronic disease that needs a chronic trPractice Pearls for PDT
https://practicaldermatology.com/series/pdt-in-practice/practice-pearls-for-pdt/20213/Jill S. Waibel, MD a Miami dermatologist specializing in laser surgery, cosmetic dermatology, and medical dermatology, discusses her background in the use of photodynamic therapy (PDT) and provides insight into off-label PDT treatments she provides her patients. Dr. Waibel is a world-recognized leadExosome Therapy: Explained
https://practicaldermatology.com/conferences/scale-2023/exosome-therapy-explained/20200/Jane Yoo, MD, explains exactly what exosomes are and highlights some current therapeutic uses for exosome therapy including treating hair loss and reducing redness after laser skin resurfacing.Eyeing a Treatment for Syringoma
https://practicaldermatology.com/series/scientifically-speaking/eyeing-a-treatment-for-syringoma/20112/Listen as Joel L. Cohen, MD describes early evidence for the use of nano pulse stimulation to treat syringoma, a notoriously challenging target.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneScientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P